Riferminogene Pecaplasmid

Summary

Riferminogene Pecaplasmid (CHEMBL2108293) is a phase-3 clinical-stage gene; indicated across 3 conditions including peripheral vascular disease and peripheral arterial disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 3 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108293
Name	Riferminogene Pecaplasmid
Type	Gene
Max phase	3

Also known as: Nv1fgf, Riferminogen pecaplasmido, Riferminogene pecaplasmid, XRP-0038, XRP0038, RIFERMINOGENE PECAPLASMID

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peripheral vascular disease	3	MONDO:0005294	EFO:0003875
peripheral arterial disease	2	MONDO:0005386	EFO:0004265

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00566657	PHASE3	COMPLETED	Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions
NCT00368797	PHASE2	COMPLETED	Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
NCT00798005	PHASE2	COMPLETED	Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
NCT01157871	PHASE2	COMPLETED	Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication
NCT01157143	PHASE1	COMPLETED	Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation
NCT01157156	PHASE1	COMPLETED	Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).